Therapies / RNA / Genetics / Therapeutics / Protein / National blog main / San Francisco / San Francisco blog main / San Francisco top stories / Texas blog main / Texas top stories / Biotech / Colt Ventures / Cystic Fibrosis / genetic disease / Hunt Technology Ventures / Life Sciences / Lung Diseases / MPM Capital / OrbiMed Advisors / Osage University Partners / ReCode Therapeutics / TranscripTx / Vida Ventures

With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases

Posted On: Mar 26, 2020   |   Posted By: Xconomy

With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases

Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year two investigational treatments that use types of RNA to tweak mutated proteins. Dallas company ReCode Therapeutics and Menlo Park, CA-based TranscripTx have merged under the ReCode name and leadership of CEO David Lockhart to advance treatments for progressive pulmonary diseases caused by genetic mutations. On Thursday the company announced it would put proceeds from the Series A financing toward continued preclinical work on its lead programs, investigational therapies for two genetic pulmonary diseases: primary ciliary dyskinesia and...

Continue reading ...